ASTRAZENECA has revealed that its COVID-19 vaccine contributed $275 million in sales and shaved off three cents per share from its first-quarter earnings, as the drugmaker reported better-than-expected results and forecast sales growth. This is the first time the drugmaker has given financial details from the distribution and sales of its vaccine. It has said it will not make a profit from the shot during the pandemic. Vaccine revenue included delivery of about 68 million doses worldwide, it said. Sales in Europe were $224 million, emerging market sales were $43 million, and $8 million in the rest of the world,…